biostudies-literatureUnknown29(4)Hayashi S<h4>Background</h4>In 2018, BRACAnalysis® was covered by medical insurance in Japan as a companion diagnostic test for the poly ADP-ribose polymerase inhibitor olaparib. In April 2020, eligibility for BRCA1/2 genetic testing was expanded to the diagnosis of hereditary breast and ovarian cancer syndrome, and medical management including prophylactic surgery and surveillance were covered by public insurance for BRCA1/2 mutation carriers who developed breast or ovarian cancer. The amount of BRCA1/2 genetic testing has been increasing recently, but the number of subjects and the impact of testing for patients' outcomes remain unclear.<h4>Patients and methods</h4>This study explored the potential number of patients who will be eligible for new insurance coverage for BRCA1/2 genetic testing. We Breast cancer (Tokyo, Japan)659-665https://www.ebi.ac.uk/biostudies/studies/S-EPMC9225975biostudies-literatureGenetic medicine is accelerating in Japan.PMC9225975Nakamura MMorisaki TTakao YHayashi SKaneshiro KShimazaki AYamada MKubo MKai MShikada SfalseGenetic medicine is accelerating in Japan.<h4>Background</h4>In 2018, BRACAnalysis® was covered by medical insurance in Japan as a companion diagnostic test for the poly ADP-ribose polymerase inhibitor olaparib. In April 2020, eligibility for BRCA1/2 genetic testing was expanded to the diagnosis of hereditary breast and ovarian cancer syndrome, and medical management including prophylactic surgery and surveillance were covered by public insurance for BRCA1/2 mutation carriers who developed breast or ovarian cancer. The amount of BRCA1/2 genetic testing has been increasing recently, but the number of subjects and the impact of testing for patients' outcomes remain unclear.<h4>Patients and methods</h4>This study explored the potential number of patients who will be eligible for new insurance coverage for BRCA1/2 genetic testing. We 2022-01-01T00:00:00Z2022 Jul2025-05-29T19:01:57.841Z2024-10-19T08:37:14.59ZS-EPMC92259753519100910.1007/s12282-022-01342-4